^
Association details:
| Biomarker: | KIT mutation |
|---|---|
| Cancer: | Melanoma |
| Drug: | Qinlock (ripretinib) (c-KIT inhibitor, FLT3 inhibitor, PDGFR α inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Efficacy and safety of ripretinib in patients with KIT-altered metastatic melanoma
Published date:
06/23/2022
Excerpt:
Patients with KIT-altered metastatic melanoma were enrolled and treated with ripretinib at the recommended phase II dose of 150 mg once daily in 28-day cycles….In this phase I study, ripretinib demonstrated encouraging efficacy and a well-tolerated safety profile in patients with KIT-altered metastatic melanoma, suggesting ripretinib may have a clinically meaningful role in treating these patients.
DOI:
10.1016/j.esmoop.2022.100520
Source:
Title:
1082P-Phase I study of ripretinib, a broad-spectrum KIT and PDGFRA inhibitor, in patients with KIT-mutated or KIT-amplified melanoma
Published date:
09/13/2021
Excerpt:
...of 26 pts enrolled with KIT-altered melanoma...Confirmed ORR was 23% (1 complete, 5 partial responses). Median PFS was 7.3 months, with a median duration of response of 7.4 months....Preliminary results show ripretinib had a manageable safety profile and demonstrated encouraging efficacy in KIT-altered melanoma with 23% ORR and 7.3 months mPFS, indicating that ripretinib may have a role in treating these pts.
Trial ID:
